A Study of YL-17231 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety,
tolerance and PK of oral YL-17231 in patients with advanced solid tumors with KRAS mutation,
so as to confirm the recommended phase 2 dose of YL-17231 and obtain the preliminary efficacy
information of patients with advanced solid tumors with KRAS mutation.